<DOC>
	<DOCNO>NCT00796484</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability XL888 subject solid tumor . XL888 potent selective inhibitor HSP90 , key component molecular chaperone complex promote conformational maturation stabilization diverse client protein . Many HSP90 client protein play critical role signal pathway implicate tumor cell growth , proliferation , survival .</brief_summary>
	<brief_title>Safety Study Pharmacokinetics XL888 Adults With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Subject histologicallyconfirmed tumor metastatic unresectable long respond therapy know prolong survival standard therapy , disease effective therapy exists . 2 . For subject enrol maximum tolerate dose expansion cohort : Subject document evidence Her2overexpressing tumor ; OR Subject NSCLC progress prior response erlotinib gefitinib ; OR Subject histologicallyconfirmed , metastatic melanoma . For subject expansion cohorts A C : tumor tissue must accessible biopsy subject must willing undergo tumor biopsy . 3 . The subject ≥ 18 year old . 4 . The subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . 5 . The subject 's weight ≥ 40 kg . 6 . The subject adequate organ marrow function . 7 . The subject capable understanding comply protocol requirement sign informed consent document . 8 . Sexually active subject ( male female ) must use accepted method contraception course study 3 month last dose XL888 . 9 . Female subject childbearing potential must negative pregnancy test screening . 1 . The subject receive cytotoxic chemotherapy ( include investigational cytotoxic chemotherapy ) biologic therapy ( cytokine , antibody ) within 3 week ( nitrosoureas mitomycin C within 6 week ) first dose XL888 . 2 . The subject receive prior treatment small molecule kinase inhibitor ( include investigational kinase inhibitor ) hormonal therapy within 14 day first dose XL888 . 3 . The subject receive type investigational agent within 28 day first dose study treatment . 4 . The subject previouslyidentified allergy hypersensitivity component study treatment formulation . 5 . The subject recover clinicallymeaningful toxicity due prior therapy . 6 . The subject previously treat HSP90 inhibitor 7 . The subject untreated uncontrolled brain metastasis evidence leptomeningeal involvement disease . 8 . The subject currently receive anticoagulation therapeutic dose warfarin . 9 . The subject uncontrolled intercurrent illness include , limited : ongoing active infection ; diabetes mellitus ; hypertension ; symptomatic congestive heart failure , unstable angina pectoris , stroke myocardial infarction within 3 month . 10 . The subject baseline correct QT interval ( QTc ) &gt; 460 ms. 11 . The subject pregnant breastfeeding . 12 . The subject know positive human immunodeficiency virus ( HIV ) . 13 . The subject unable unwilling abide study protocol cooperate fully investigator designee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>